Translational Medicine in Autoimmunity Organizer(s): Lloyd H. Kasper, David A. Hafler and Lucienne Chatenoud Date: January 08 - 13, 2005
Location: Big Sky Resort, Big Sky, MT, USARecent advances in the understanding of basic mechanisms of autoimmune disease have led to the development of reagents that can potentially interfere with the disease process and limit disease progression. Some of these therapeutics have already been proven effective in the treatment of autoimmune conditions. This meeting will focus on the use of novel therapeutics for the treatment and management of several autoimmune diseases including multiple sclerosis, inflammatory bowel disease, diabetes, systemic lupus and rheumatoid arthritis. Information will be presented that highlights new findings that 'bridge' the gap between bench and bedside. Particular emphasis will be placed on the translational therapeutics between pre-clinical and Phase I/II research. This will include such topics as blocking of co-stimulation, T cell trafficking, Th1 cytokine production (IL-12 and IL-23), T cell receptor vaccination, islet cell transplantation, chemokine antagonists and signal transduction pathway inhibitors. The application of these novel approaches to specific disease process will be examined and will provide insight into clinical disease management. Discounted Abstract Deadline: September 16 2004 Discounted Registration Deadline: November 8 2004 We gratefully acknowledge additional in-kind support for this conference from those foregoing speaker expense reimbursements:
Biogen Idec
|